Poly Medicure (531768) Q4 97/98 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 97/98 earnings summary
2 Nov, 2026Executive summary
First operating-period results to 31 Mar 1998: gross revenue Rs 526.52 lakh and net profit Rs 4.51 lakh; commercial production began 9 Apr 1997.
Production reached 51.06 lakh medical disposables, equal to 42.6% of installed capacity; products received ISO 9002 certification.
Financial highlights
Gross revenue Rs 526.52 lakh; total expenditure Rs 363.98 lakh; interest and finance charges Rs 85.44 lakh.
Profit after interest but before depreciation and tax was Rs 77.10 lakh; depreciation Rs 72.03 lakh; PBT Rs 5.07 lakh; net profit Rs 4.51 lakh.
Product sales were Rs 512.06 lakh; other income Rs 14.46 lakh and increase in stocks Rs 26.69 lakh in the first P&L period.
Net profit was Rs 4.51 lakh against prospectus projection of Rs 181 lakh; actual total income Rs 526.52 lakh versus projected Rs 1,530 lakh.
Outlook and guidance
Management expected production and sales in 1998-99 to exceed the prior period despite tough competition in domestic and export markets.
Blood-bag sales were expected to improve through direct supply to government blood banks.
Latest events from Poly Medicure
- Acquisition-led revenue growth and a European rebound faced pressure on consolidated margins.531768
Q2 26/27 - Commercial production began in Apr 1997 after delays; FY turnover and PBT were nil.531768
Q4 96/97 - Revenue and production grew, but depreciation drove a FY99 net loss.531768
Q4 98/99 - Profit returned as production grew 77.10% and export turnover nearly doubled.531768
Q4 99/00 - Higher production lifted profit, while commissioned expansion set up the next growth phase.531768
Q4 01/02 - FY04 growth and capacity expansion advanced, with exports at 83.8% of sales.531768
Q4 03/04 - Profit and exports surged as capacity expansion and Egypt production plans advanced.531768
Q4 02/03 - Record production and higher profit fuel expansion amid pricing and currency pressures.531768
Q4 05/06 - Sales rose 31.2%, PAT climbed 40.4%, and exports reached 86.4% of sales.531768
Q4 04/05